BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21672921)

  • 1. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression.
    Chung DW; Rudnicki DD; Yu L; Margolis RL
    Hum Mol Genet; 2011 Sep; 20(17):3467-77. PubMed ID: 21672921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.
    Khaled HG; Feng H; Hu X; Sun X; Zheng W; Li PP; Rudnicki DD; Ye W; Chen YC; Southall N; Marugan J; Ross CA; Ferrer M; Henderson MJ; Margolis RL
    Sci Rep; 2021 Mar; 11(1):6157. PubMed ID: 33731741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.
    Goold R; Flower M; Moss DH; Medway C; Wood-Kaczmar A; Andre R; Farshim P; Bates GP; Holmans P; Jones L; Tabrizi SJ
    Hum Mol Genet; 2019 Feb; 28(4):650-661. PubMed ID: 30358836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range.
    Majumder P; Raychaudhuri S; Chattopadhyay B; Bhattacharyya NP
    Cell Mol Neurobiol; 2007 Dec; 27(8):1127-45. PubMed ID: 17902043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.
    Gipson TA; Neueder A; Wexler NS; Bates GP; Housman D
    RNA Biol; 2013 Nov; 10(11):1647-52. PubMed ID: 24256709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
    Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
    Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
    Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
    Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.
    Sathasivam K; Neueder A; Gipson TA; Landles C; Benjamin AC; Bondulich MK; Smith DL; Faull RL; Roos RA; Howland D; Detloff PJ; Housman DE; Bates GP
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2366-70. PubMed ID: 23341618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
    Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
    Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
    Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
    J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated silencing of huntingtin expression by shRNA.
    Huang B; Kochanek S
    Hum Gene Ther; 2005 May; 16(5):618-26. PubMed ID: 15916486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.